User login
Key clinical point: In patients with episodic migraine (EM), erenumab reduced both monthly migraine days (MMD) and monthly migraine attacks (MMA) by a similar magnitude. However, the impact on migraine attack duration was minor.
Major finding: Erenumab 70 mg and 140 mg vs. placebo were associated with a greater reduction in MMD (least square mean percent change [LSM%], −39% and −44% vs. 22%) and MMA (LSM%, −40% and −43% vs. −26%). The percentage change from baseline in migraine attack duration was minor with erenumab 70 mg and 140 mg vs. placebo (LSM%, −7% and −8% vs. −1%).
Study details: Findings are from a post hoc analysis of phase 3 STRIVE study including 955 patients with EM who were randomly allocated to receive either erenumab 70 mg or 140 mg or placebo once monthly for 6 months.
Disclosures: The study was supported by Amgen Inc., Thousand Oaks, CA, USA. HC Diener and M Ashina reported receiving honoraria, financial support, and/or serving as a consultant, speaker, or scientific advisor or primary investigator for various sources. GPDS Lima and S Rasmussen declared being employees and holding stocks at Amgen Inc.
Source: Diener HC et al. Cephalalgia. 2021 May 3. doi: 10.1177/03331024211010308.
Key clinical point: In patients with episodic migraine (EM), erenumab reduced both monthly migraine days (MMD) and monthly migraine attacks (MMA) by a similar magnitude. However, the impact on migraine attack duration was minor.
Major finding: Erenumab 70 mg and 140 mg vs. placebo were associated with a greater reduction in MMD (least square mean percent change [LSM%], −39% and −44% vs. 22%) and MMA (LSM%, −40% and −43% vs. −26%). The percentage change from baseline in migraine attack duration was minor with erenumab 70 mg and 140 mg vs. placebo (LSM%, −7% and −8% vs. −1%).
Study details: Findings are from a post hoc analysis of phase 3 STRIVE study including 955 patients with EM who were randomly allocated to receive either erenumab 70 mg or 140 mg or placebo once monthly for 6 months.
Disclosures: The study was supported by Amgen Inc., Thousand Oaks, CA, USA. HC Diener and M Ashina reported receiving honoraria, financial support, and/or serving as a consultant, speaker, or scientific advisor or primary investigator for various sources. GPDS Lima and S Rasmussen declared being employees and holding stocks at Amgen Inc.
Source: Diener HC et al. Cephalalgia. 2021 May 3. doi: 10.1177/03331024211010308.
Key clinical point: In patients with episodic migraine (EM), erenumab reduced both monthly migraine days (MMD) and monthly migraine attacks (MMA) by a similar magnitude. However, the impact on migraine attack duration was minor.
Major finding: Erenumab 70 mg and 140 mg vs. placebo were associated with a greater reduction in MMD (least square mean percent change [LSM%], −39% and −44% vs. 22%) and MMA (LSM%, −40% and −43% vs. −26%). The percentage change from baseline in migraine attack duration was minor with erenumab 70 mg and 140 mg vs. placebo (LSM%, −7% and −8% vs. −1%).
Study details: Findings are from a post hoc analysis of phase 3 STRIVE study including 955 patients with EM who were randomly allocated to receive either erenumab 70 mg or 140 mg or placebo once monthly for 6 months.
Disclosures: The study was supported by Amgen Inc., Thousand Oaks, CA, USA. HC Diener and M Ashina reported receiving honoraria, financial support, and/or serving as a consultant, speaker, or scientific advisor or primary investigator for various sources. GPDS Lima and S Rasmussen declared being employees and holding stocks at Amgen Inc.
Source: Diener HC et al. Cephalalgia. 2021 May 3. doi: 10.1177/03331024211010308.